跳到主要內容

Detheux Michel 的 Form 4 申報

iTeos Therapeutics, Inc.(ITOS),2021/12/22 申報

申報編號
0001209191-21-070996
申報時間
2021/12/22
交易日
2021/12/2-12/22
申報延遲
20 天遲報
10b5-1 計畫
表單沒有這欄(2023 年以前)

這份申報列了 10 筆非衍生性交易、13 筆衍生性交易。公開市場賣出合計 $198.2 萬。交易後 20 天才申報,超過 2 個營業日的期限。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Detheux MichelCIK 0001816196高階主管(執行長)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2021/12/20Common StockM行使選擇權取得+9,111$4.30+$39,177.387,311直接
2021/12/20Common StockS賣出處分−9,111$43.94F2−$400,337.3478,200直接
2021/12/21Common StockM行使選擇權取得+19,226$4.30+$82,671.897,426直接
2021/12/21Common StockS賣出處分−13,646$44.15F3−$602,470.983,780直接
2021/12/21Common StockS賣出處分−5,580$45.06F4−$251,434.878,200直接
2021/12/22Common StockM行使選擇權取得+1,663$4.30+$7,150.979,863直接
2021/12/22Common StockS賣出處分−1,514$44.31F5−$67,085.3478,349直接
2021/12/22Common StockS賣出處分−149$44.92−$6,693.0878,200直接
2021/12/22Common StockS賣出處分−5,007$44.62F6−$223,412.3473,193直接
2021/12/22Common StockS賣出處分−9,493$45.37F7−$430,697.4163,700直接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2021/12/2Common StockG贈與處分−403,442$0.00$090,000直接
2021/12/2Common StockG贈與取得+313,442$0.00$0313,442間接
2021/12/2Common StockG贈與處分−340,964$0.00$0155,964直接
2021/12/2Common StockG贈與取得+185,000$0.00$0185,000間接
2021/12/2Common StockG贈與處分−70,244$0.00$017,544直接
2021/12/2Common StockG贈與取得+52,700$0.00$052,700間接
2021/12/2Common StockG贈與處分−1,035,424$0.00$0258,824直接
2021/12/2Common StockG贈與取得+776,600$0.00$0776,600間接
2021/12/2Common StockG贈與處分−144,000$0.00$037,800直接
2021/12/2Common StockG贈與取得+106,200$0.00$0106,200間接
2021/12/20Common StockM行使選擇權處分−9,111$0.00$080,889直接
2021/12/21Common StockM行使選擇權處分−19,226$0.00$061,663直接
2021/12/22Common StockM行使選擇權處分−1,663$0.00$060,000直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.2, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.825 to $45.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.85 to $44.73, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.15 to $45.83, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)